KLK3 and prostate cancer: [Polypodiaceae], Foreknowledge) In a randomized controlled trial of 44 patients with advanced prostate cancer (APC), YJQR treatment with endocrine therapy for 6 months increased prostate specific antigen (PSA), free PSA (f-PSA) and hemoglobin (Hb) in serum.